The theme of World Diabetes Day 2026 is "Early Action on Diabetes." Its focus is on early recognition, preventive measures through a healthy lifestyle and fair access to healthcare and prejudice-free services. Though everyone is aware of the primary diabetes tests, including Fasting Plasma Glucose (FPG), Postprandial (PP) Glucose test and HbA1c test, there are many less popular tests - blood and urine tests- which, though not very popular, can provide crucial knowledge about the work of insulin, the type of diabetes, its progression, and an individual's chance to develop complications. The tests for diabetes can be divided into screening and diagnosis tests, monitoring tests and prognostic tests. The use of these tests is beneficial because of their ability to detect abnormalities in metabolism early and to carry out timely medical measures.

Evaluating the type of diabetes:

When an individual's body does not either produce sufficient levels of insulin or use that insulin properly, diabetes occurs. Type 1 diabetes occurs due to the immune system attacking the β-cells of the pancreas that make insulin, while Type 2 diabetes involves insulin resistance in the body's cells. Various diagnostic tests help differentiate these types of diabetes.

1. Diabetes autoantibody tests

In suspected Type 1 diabetes, autoantibody testing helps identify whether the immune system is attacking insulin-producing pancreatic beta cells. Important investigations include:

  • GAD65 Antibodies (GADA): One of the most commonly detected markers of autoimmune diabetes
  • Islet Cell Antibodies (ICA): Detect antibodies directed against pancreatic islet cells
  • Insulin Autoantibodies (IAA): Often detected early in children with Type 1 diabetes, particularly before insulin treatment begins
  • IA-2 Antibodies (IA-2A): Target proteins associated with pancreatic beta cells
  • Zinc Transporter 8 Antibodies (ZnT8A): Help identify autoimmune damage to insulin-producing cells

These tests are particularly useful in distinguishing Type 1 diabetes from Type 2 diabetes and identifying Latent Autoimmune Diabetes in Adults (LADA).

2. C-Peptide test

C-peptide is released when the pancreas produces insulin and serves as an indicator of the body's own insulin production. Low or undetectable C-peptide levels may indicate reduced insulin production, as seen in Type 1 diabetes, while normal or high levels may be observed in Type 2 diabetes, particularly during its earlier stages. This test helps assess pancreatic beta-cell function and guide treatment decisions.

Tests that reveal insulin resistance:

3. Fasting insulin test

This test measures insulin levels in the blood after fasting and may help assess insulin production and possible insulin resistance. Elevated insulin levels, particularly when accompanied by normal or mildly elevated blood glucose, may indicate that the pancreas is producing more insulin to compensate for reduced insulin sensitivity.

4. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)

HOMA-IR is a calculated index based on fasting glucose and fasting insulin levels. It provides an estimate of insulin resistance and helps assess metabolic health. It is primarily used in research and selected clinical settings rather than as a routine diagnostic test for diabetes.

5. Adiponectin test

Adiponectin is a hormone produced by fat cells that plays an important role in regulating glucose metabolism and insulin sensitivity. Higher levels are generally associated with better insulin sensitivity, while lower levels have been linked to increased insulin resistance and metabolic risk. Although it is a useful research biomarker, it is not routinely recommended for diagnosing diabetes.

Lesser-known tests for monitoring blood sugar:

6. Fructosamine test

Unlike HbA1c, which reflects average blood glucose over approximately 2–3 months, fructosamine measures glycated blood proteins and provides an estimate of average blood glucose over the preceding 2–3 weeks. It can be particularly useful when short-term glucose monitoring is required or when HbA1c results may be unreliable due to certain haemoglobin or red blood cell disorders.

7. Anti-insulin antibody testing

In some individuals receiving insulin therapy, the immune system may develop antibodies against administered insulin. These antibodies can occasionally affect insulin availability and activity. Testing may be considered in selected patients with unexplained glucose fluctuations or unusual responses to insulin treatment.

Tests that detect diabetes-related complications early:

Diabetes can affect several organs, particularly the kidneys, heart, liver and eyes. Some complications may develop silently, making regular screening important even when symptoms are absent.

8. Urine Albumin-to-Creatinine Ratio (UACR) and Kidney function tests

Diabetic kidney disease is one of the most common complications of diabetes. Urine Albumin-to-Creatinine Ratio (UACR) helps detect small amounts of albumin in urine, which may indicate early kidney damage. Serum creatinine and Estimated Glomerular Filtration Rate (eGFR) help assess kidney function. Blood Urea Nitrogen (BUN) and electrolytes may also be evaluated when clinically indicated.

9. Lipid profile

People with diabetes are at an increased risk of cardiovascular complications. A lipid profile measures total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides to assess cardiovascular risk and guide preventive treatment.

10. Liver function tests

Individuals with Type 2 diabetes and insulin resistance are at an increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). Liver function tests may help identify abnormalities that warrant further evaluation.

11. Thyroid function tests

Autoimmune thyroid disorders are more common among people with Type 1 diabetes. Thyroid function testing, including TSH and, when indicated, thyroid hormone and antibody tests, may be recommended to identify associated thyroid abnormalities.

Early testing can make a difference:

While fasting blood glucose, postprandial glucose and HbA1c remain the cornerstone of diabetes diagnosis and monitoring, lesser-known investigations provide additional information about insulin production, insulin resistance, disease classification and potential complications. Not every individual requires all these tests; their selection depends on the type and duration of diabetes, clinical symptoms, risk factors and treatment history.

Early screening, appropriate investigations and regular follow-ups, guided by a treating physician, can help identify metabolic abnormalities and complications before they become severe. Timely diagnosis and intervention are essential not only for improving glycaemic control but also for protecting long-term health and quality of life.

The author is a consultant pathologist at Metropolis Healthcare Ltd. (Mumbai). 

 

The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.

Disclaimer: Comments posted here are the sole responsibility of the user and do not reflect the views of THE WEEK. Obscene or offensive remarks against any person, religion, community or nation are punishable under IT rules and may invite legal action.